title: Intubation conditions following rocuronium: influence of induction agent and priming.
abstract: A small priming dose of rocuronium can shorten the onset time of neuromuscular blockade. Induction agents with less cardiovascular depression also reduce the onset time. We hypothesized that ketamine, compared to thiopentone, would reduce onset time and improve intubating conditions following priming. Sixty patients ASA I to II, randomized by computer-generated sequence to four groups were investigated in a double-blind controlled trial. In the two groups with priming, 0.04 mg/kg of rocuronium was followed by three minutes of priming interval. Induction was followed by an intubation dose of 0.4 mg/kg of rocuronium. After 30 seconds, intubation was attempted within a further 20 seconds. In the two control groups, the same sequence was repeated except sham priming (saline) was given. For induction, S-ketamine (1 mg/kg) or thiopentone (4 mg/kg) were administered. Intubating conditions were graded as excellent, good, poor, or not possible. Neuromuscular transmission was monitored by acceleromyography of the thumb. There were no measured differences in onset time of neuromuscular block or in haemodynamics between the groups. The proportion of good to excellent intubating conditions was higher when ketamine was preceded by priming compared to ketamine without priming (87% vs 20%; P<0.05). In both priming and control groups intubating conditions were improved when using ketamine compared to thiopentone (P<0.05). The mechanism of this effect was not clear from this study.
authors.affiliation: Department of Anaesthesia and Intensive Care, Santa Maria degli Angeli Hospital, Pordenone, Italy.
authors.forename: Y
authors.initials: Y
authors.lastname: Leykin
authors.forename: T
authors.initials: T
authors.lastname: Pellis
authors.forename: M
authors.initials: M
authors.lastname: Lucca
authors.forename: A
authors.initials: A
authors.lastname: Gullo
mesh_terms: D000328:Adult; D000700:Analgesics / Q000008:administration & dosage* / Q000494:pharmacology; D000732:Androstanols / Q000008:administration & dosage* / Q000494:pharmacology; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007442:Intubation, Intratracheal / Q000379:methods*; D007649:Ketamine / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009213:Myography / Q000379:methods; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000077123:Rocuronium; D012965:Sodium Chloride / Q000008:administration & dosage; D013874:Thiopental / Q000008:administration & dosage* / Q000494:pharmacology; D013933:Thumb / Q000502:physiology; D013997:Time Factors
chemical_list: D000700:Analgesics; D000732:Androstanols; D018686:Anesthetics, Intravenous; D003473:Neuromuscular Nondepolarizing Agents; D012965:Sodium Chloride; D007649:Ketamine; D013874:Thiopental; D000077123:Rocuronium